COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

To find the safest and most tolerable dose of CAR.B7-H3 T cells to administer in patients with relapsed/refractory platinum-resistant epithelial ovarian cancer.

Age & Gender

18 years ~ 99 years
Female

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

United States (Nationwide)

Additional Study Information

Principal Investigator

Linda Van Le
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers), Ovarian)

IRB Number

20-1673

ClinicalTrials.gov

NCT04670068

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.